EPIAO is an injectable recombinant human erythropoietin (rhEPO). Erythropoietin (EPO) is a natural growth factor produced in healthy kidneys that regulates production of red blood cells. EPIAO and other rhEPO products are used to stimulate the production of red blood cells in patients with anemia.

TPIAO is a recombinant human thrombopoietin (rhTPO) product used for the treatment of certain types of thrombocytopenia, a deficiency of platelets. Thrombopoietin (TPO) is a hemopoietic, or blood or blood cell-related, growth factor protein.

Intefen is a recombinant human interferon alpha-2a product for the treatment of malignancies of the lymphatic or hematopoietic system, and viral infectious diseases, including adult chronic hepatitis B, acute and chronic hepatitis C and genital warts.


Inleusin is a recombinant human interleukin 2 (IL-2) product that is structurally and functionally similar to naturally produced IL-2, an immune regulator. IL-2 is a natural part of the human immune response to microbial infection.


Etanercept was marketed in 2005, and is the first antibody fusion protein medicine marketed in the rheumatism field of China. 2 kinds of indications were approved by CFDA: Treatment of rheumatoid arthritis (approved in 2005), ankylosing spondylitis and psoriasis (approved in 2007).

Press Releases

Please refer to the Announcements & Circulars section for additional corporate updates

- more press releases -